Drug Trial Radar · NCT03602859
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,400
Actual
Start
Oct 11, 2018
Primary completion
Oct 31, 2024
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Tesaro, Inc.GSK (GSK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Jul 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the progression-free survival (PFS) for participants receiving dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus participants receiving SOC with chemotherapy followed by niraparib maintenance. This comparison will be investigated in participants of newly diagnosed stage III or IV advanced non-mucinous epithelial ovarian cancer participants and also to compare PFS of all participants with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab (TSR-042), and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2.
Conditions
- Ovarian Neoplasms
- Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions
NiraparibDrug
Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
Dostarlimab (TSR-042)Drug
Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
Standard of careDrug
Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
Dostarlimab-PlaceboDrug
Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
Niraparib-PlaceboDrug
Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to approximately 316 weeks
Locations
182 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Anchorage, Alaska
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Farmington, Connecticut
GSK Investigational Site
Hartford, Connecticut
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Geneva, Illinois
GSK Investigational Site
Warrenville, Illinois
GSK Investigational Site
Zion, Illinois
GSK Investigational Site
Covington, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Shreveport, Louisiana
GSK Investigational Site
Scarborough, Maine
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Silver Spring, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Springfield, Massachusetts
GSK Investigational Site
Worcester, Massachusetts
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Billings, Montana
GSK Investigational Site
Neptune City, New Jersey
GSK Investigational Site
Teaneck, New Jersey
GSK Investigational Site
Hawthorne, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Stony Brook, New York
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Canton, Ohio
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Eugene, Oregon
GSK Investigational Site
Portland, Oregon
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.